Answers are grounded in this paper and cite their sources.
Long delays before insulin initiation and intensification in clinically eligible patients are largely driven by concerns over hypoglycemia. New diabetes technology that provides continuous glucose monitoring may reduce occurrences of hypoglycemia and help overcome therapeutic inertia associated with insulin initiation and intensification.
No takes yet. Share an insight, caveat, or question.
Gavin et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: